1 y of single oral doses of 4 to 160 mg of the calcium-receptor agonist drug R-568 in 20 postmenopausal

2 ingle agent to rats, the previously reported calcium receptor antagonist 3 elicited a sustained eleva

3    We then demonstrated the existence of the calcium receptor (CaR) in keratinocytes and determined t

4 nd we have used in situ hybridization to map calcium receptor (CaR) mRNA expression in the adult rat

5                   The C-terminal tail of the calcium receptor (CaR) regulates the affinity of the rec

6 eecham compound collection against the human calcium receptor (CaR) resulted in the identification of

7  may be modulated by local expression of the calcium receptor (CaR), the vitamin D receptor (VDR), an

8 ynaptic scaling is mediated by GluA2-lacking calcium receptors (CP-AMPARs), whereas others have found

9                           The discovery of a calcium receptor has stimulated interest in the signalin

10  the extracellular domain (ECD) of the human calcium receptor (hCaR) from the medium of HEK-293 cells

11                                    The human calcium receptor (hCaR) is a G-protein-coupled receptor

12 (1075) in the carboxyl terminus of the human calcium receptor (hCaR), which causes autosomal dominant

13 residue cytoplasmic carboxyl terminus of the calcium receptor in cell-surface expression and signal t

14  osteoblastic niche, such as quiescence, and calcium receptor, N-cadherin, Notch1, and p21 are higher

15                        The G-protein-coupled calcium receptor plays a key role in extracellular calci

16 f the interactions between the intracellular calcium receptor protein calmodulin (CaM) and one of its

17 f drugs that increase the sensitivity of the calcium receptor to ionized calcium.